X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$0.66 USD
-0.05 (-6.69%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $0.66 0.00 (-0.38%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
X4 Pharmaceuticals, Inc. [XFOR]
Reports for Purchase
Showing records 21 - 40 ( 96 total )
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 Update - Big Year for Mavorixafor With 3 Clinical Data Updates
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Potential Mavorixafor NDA for WHIM in 2H23; Lower PT to $8.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
WHIM Phase 3 Top Line in 4Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 - Topline WHIM Data in 4Q22 to Support NDA in 2H2023
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Highlights Mavorixafor''s Broad Commercial Potential, PT to $28
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mavorixafor Delivers at ASH, Some Hiccups, But Outlook Remains Solid
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mavorixafor?s Potential in WM Decreased, but Not Gone; Lower PT to $11; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Momentum Builds Ahead of X4''s ASH Update This Weekend, Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Companies With YE2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Pipeline Updates Expected at ASH; Investor Day on December 16; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Update - Multiple ASH Updates Should Set Clear Expecations for 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Two Key Appointments Hint at Mavorixafor''s Strong Commercial Potential
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z